You are here: Industry Insights > Market News > Italy's AIFA approves using different vaccine for second dose after AstraZeneca jab

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Italy's AIFA approves using different vaccine for second dose after AstraZeneca jab

firstwordpharmaJune 15, 2021

Tag: AstraZeneca , COVID-19 , Vaccine

Favorites

Italy's medicine agency AIFA said Italians under the age of 60 who received a first dose of the AstraZeneca COVID-19 vaccine Vaxzevria can be given a different vaccine when they get their second dose, as reported in Yahoo!News.

Italy's AIFA approves using different vaccine for second dose after AstraZeneca jab

Last week, Italy restricted the use of Vaxzevria to people over the age of 60, after a teenager who had received the shot died from a rare form of blood clotting.

"Based on clinical studies published in the last few weeks, AIFA's scientific committee has decided to approve the vaccine mix," AIFA said in a statement, adding vaccines developed by Pfizer and Moderna could be administered to people who first got an AstraZeneca jab.

Previous:Weight-Loss Surgeries Used Least in U.S. States That Need Them Most

Next:Good News, Bad News From Alzheimer's Vaccine Trial

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Italy's AIFA approves using different vaccine for second dose after AstraZeneca jab | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Italy's AIFA approves using different vaccine for second dose after AstraZeneca jab

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Italy's AIFA approves using different vaccine for second dose after AstraZeneca jab

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>